Compare IIIV & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IIIV | ALT |
|---|---|---|
| Founded | 2012 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 427.0M | 421.5M |
| IPO Year | 2018 | 2005 |
| Metric | IIIV | ALT |
|---|---|---|
| Price | $16.36 | $2.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $33.20 | $17.67 |
| AVG Volume (30 Days) | 432.8K | ★ 4.4M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ 0.24 | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | $9.05 | N/A |
| Revenue Next Year | $8.07 | N/A |
| P/E Ratio | $69.29 | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $16.00 | $2.56 |
| 52 Week High | $33.97 | $6.44 |
| Indicator | IIIV | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 28.11 | 48.02 |
| Support Level | N/A | $2.87 |
| Resistance Level | $23.52 | $3.09 |
| Average True Range (ATR) | 1.17 | 0.17 |
| MACD | -0.55 | -0.01 |
| Stochastic Oscillator | 5.17 | 26.42 |
i3 Verticals Inc provides mission-critical enterprise software solutions to public sector entities. These comprehensive cloud-native solutions address a broad range of government functions, including courts and public safety, public administration, utilities, transportation and schools. The company generates the majority of revenue from software and related services, including the sale of subscriptions, recurring services, ongoing support, licenses, and installation and implementation services specific to software.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.